In Table 2 we showed 10 CBL alteration NSCLC patients’ treatment outcome, Two out of ten patients had EGFR L858R/T790M mutations and had bad outcome after erlotinib treatment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.